Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    NCT01905228
Previous Study | Return to List | Next Study

A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Incuron
Sponsor:
Information provided by (Responsible Party):
Incuron
ClinicalTrials.gov Identifier:
NCT01905228
First received: July 9, 2013
Last updated: April 11, 2014
Last verified: April 2014
  Purpose

The primary objective of the study is to determine the maximally tolerated dose and recommended Phase 2 dose of CBL0137 when administered intravenously (IV) to patients with metastatic or unresectable advanced solid malignancies or refractory lymphomas.


Condition Intervention Phase
Solid Tumors
Drug: CBL0137
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas

Resource links provided by NLM:


Further study details as provided by Incuron:

Primary Outcome Measures:
  • To determine the maximally tolerated dose and recommended Phase 2 dose [ Time Frame: 30 days after last dose ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 48
Study Start Date: July 2013
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CBL0137
  • Dose Level 1: 10 mg/m2, IV (in the vein)
  • Dose Level 2: 20 mg/m2, IV (in the vein)
  • Dose Level 3: 30 mg/m2, IV (in the vein)
  • Dose Level 4: 40 mg/m2, IV (in the vein)
  • Dose Level 5: 50 mg/m2, IV (in the vein)
  • Dose Level 6: 62.5 mg/m2, IV (in the vein)
Drug: CBL0137
All doses are on Days 1, 8 and 15 of every 28 day cycle. Number of Cycles: 2 or until progression or unacceptable toxicity develops

Detailed Description:

Patients must have documented recurrent or refractory solid tumors, or refractory lymphomas; patients enrolled in the dose-expansion part of the trial must have least one lesion that may qualify as a target lesion based on the RECIST 1.1 criteria. Following the provision of signed informed consent, patients will be screened for entry into the study. Screening numbers will be assigned by the site. Patients who do not meet entry criteria will not have their screening data entered into the database.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histological or cytological evidence of a solid neoplasm or lymphoma
  • Patients enrolled in the expansion cohort must have at least one measureable lesion as defined by the RECIST 1.1 criteria
  • Patients must:

    • have metastatic or unresectable advanced solid tumors or refractory lymphomas that have recurred or progressed following standard therapy or
    • no longer be candidates for standard therapy or
    • have tumors for which there is no standard therapy
  • Patients must be ambulatory and have an ECOG Performance Score of 0 or 1;
  • Patients or their legal representative must be able to provide written informed consent;
  • Patients must have adequate bone marrow reserve as evidenced by:

    • White Blood Cell Count (WBC) > 3,000/µL
    • Absolute Neutrophil Count (ANC) > 1,500/µL
    • Platelet count (PLT) > 100,000/µL
    • Hemoglobin (HGB) > 9.0 gm/dL (patients may be transfused to achieve this HGB level);
  • Patients must have adequate hepatic function as evidenced by:

    • Serum AST/ALT < 3X the upper limit of normal (ULN) for the reference lab (< 5X the ULN for patients with known hepatic metastases)
    • Serum bilirubin < 1.5 x the ULN for the reference lab;

Exclusion Criteria:

  • Patients with active infection or with a fever > 38.50 C within 3 days of the first scheduled day of dosing;
  • Patients with primary CNS tumors or symptomatic CNS metastases who have not undergone surgery and/or radiotherapy and/or who are not neurologically stable;
  • Patients with known hypersensitivity to any of the components of CBL0137;
  • Patients who are receiving concurrent investigational therapy; for patients who have recently received investigational therapy, 5 half-lives must have elapsed between the last dose of investigational drug and the first dose of CBL0137. If the half-live is unknown, 4 weeks must have elapsed between the last dose of investigational drug and the first dose of CBL0137 (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication in the United States);
  • Males with mean QTcF values of > 450 msec and females with QTcF values of > 470 msec following 3 ECGs conducted 5 minutes apart from each other; patients who are known to have congenital prolonged QT syndromes; or patients who are on medications known to cause prolonged QT intervals on ECG;

Please speak with the PI for the complete Inclusion/Exclusion listing.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01905228

Contacts
Contact: Jean Viallet, MD 716-849-6810 jvallet@cbiolabs.cm

Locations
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Wen W Ma, MD       Wen.Ma@RoswellPark.org   
Principal Investigator: Wen W Ma, MD         
United States, Texas
CTRC at The University of Texas Healh Science Center at San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Devalingam Mahalingam, MD       mahalingam@uthscsa.edu   
Principal Investigator: Devalingam Mahalingam, MD, PhD         
Sponsors and Collaborators
Incuron
Investigators
Principal Investigator: Devalingam Mahalingam, MD The University of Texas Health Science Center at San Antonio
Principal Investigator: Wen W Ma, MD Roswell Park Cancer Institue
  More Information

No publications provided

Responsible Party: Incuron
ClinicalTrials.gov Identifier: NCT01905228     History of Changes
Other Study ID Numbers: I137-101
Study First Received: July 9, 2013
Last Updated: April 11, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Incuron:
Metastatic Advance Solid Neoplasms
Unresectable Advance Solid Neoplasms
Refractory Lymphomas

Additional relevant MeSH terms:
Lymphoma
Neoplasms
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on November 24, 2014